Actively Recruiting
Evaluating the Effectiveness and Safety of VIM0423 Oral Treatment in Adults with Isolated Dystonia Affecting Multiple Body Regions
Led by Vima Therapeutics · Updated on 2026-10-26
100
Participants Needed
45
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness, safety, and tolerability of VIM0423, an oral medication, in adults with isolated dystonia affecting two or more body regions. This rare movement disorder causes sustained muscle contractions leading to abnormal and sometimes twisting movements or postures. The study aims to determine if VIM0423 improves dystonia symptoms compared to a placebo, and if it can enhance daily function and quality of life. Participants will be randomly assigned to receive either VIM0423 or a matching placebo, taking up to six pills each evening before bed for 16 weeks. This Phase 2, double-blind, placebo-controlled trial includes a dose titration, maintenance, and tapering period. The study lasts up to 24 weeks and consists of 6 in-person visits, including screening, baseline assessments, treatment, and safety follow-up. Throughout the study, participants will undergo evaluations such as video assessments of dystonia symptoms, clinical laboratory tests, and EKGs. They will also complete self-assessments regarding the impact of dystonia on daily activities. Researchers will monitor adverse events and measure changes using the Burke-Fahn-Marsden Dystonia Rating Scale and other clinical global impression scales to assess symptom severity and improvements.
CONDITIONS
Brief Title
A Study to Evaluate the Efficacy, Safety, and Tolerability of VIM0423 in Individuals With Isolated Dystonia
Research Team
S
Study Director
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here